Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheCUP
2018-004562-33Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in cancer of unknown primary (CUP), sponsored by Heidelberg University. Primary endpoint: Progression-free survival. Started Jul 2019; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on 2018-004562-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004562-33.